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Abstract
Background: Anorexia Nervosa is a Psychiatric eating disorder of adolescence age with a high morbidity and
mortality.
Case Presentation: We describe a common case of anorexia nervosa (AN) in a female adolescent complicated by
less known conditions related to refeeding syndrome. At admission, the girl showed a mild hypercholesterolemia
with progressive normalization of the values. The initial low hypertransaminasemia worsened after refeeding until
very high levels and hypophosphoremia was also described. Only a controlled caloric intake and a specific
electrolyte supplementation led to the improvement of hematologic values and the clinical condition of the
patient.
Conclusions: Refeeding complications must be always suspected because of life-threatening risk. More attention
should be paid not only to the acute state of the disease but also to the prevention and the management of
refeeding-related manifestations.
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Background
Anorexia Nervosa (AN) is a psychiatric eating disorder
with a high morbidity and mortality rate that mainly af-
fects adolescent females aged 15 to 19 years [1]. In mal-
nourished patients depletion of fat and fat free mass lead
to reduced energy expenditure, cardiovascular alteration
and metabolic adaptation to starvation (ability to func-
tion in a hypometabolic state) so even at advanced stages
biochemical presentation of the disease is often unre-
markable. Among the few abnormal laboratory values,
hypercholesterolemia can be found despite emaciation
and avoidance of cholesterol-rich food. Several hypoth-
eses have been proposed but the improvement of serum
levels after refeeding mainly confirms the hypothesis of
accelerated cholesterol metabolism in the fasting phase
of AN [2]. The prevalence of a mild increase in serum
transaminases levels in AN patients prior to refeeding
range widely and it is observed in up to 76 % [1, 3].
Marked increases (>200 UI/L) are less common; an in-
verse relationship between aminotransferase levels and
body mass index (BMI) suggests that nutritional states
play a role in liver changes of these patients [4, 5]. In
fact it occurs when BMI reaches a critically low level [6],
particularly less than 12 kg/m2 [7]. Several factors can
contribute to determining hypertransaminasemia but the
main understanding mechanism seems to be autophagy
that is a physiological hepatoprotective event activated
by cells during episodes of stress, such as fasting [6]. It
leads to elevation of aminotransferases levels because of
increased permeability of the cytoplasmic membrane
allowing the release of transaminases in to the blood
without histological necrosis [6].
The treatment of AN is complex involving a multidis-
ciplinary approach. Regaining weight is one of the major
factors predicting favorable short and long term out-
comes, also associated with improvement in psychological
and medical complications [1]. However refeeding of
malnourished patients is not free of complications: the* Correspondence: mrosaria.marchili@opbg.net
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refeeding syndrome (RS) is the most frequent one [8]
characterized by severe intracellular electrolyte shift with
consequent low-serum electrolyte concentrations, acute
circulatory fluid overload and organ failure [9]. The cause
of RS is an excess or unbalanced oral, enteral or parenteral
nutritional intake [9] and the risk of its development is
highest during the first week [10]. According to NICE
guidelines (2004) the patients in greatest danger have a
BMI <16 kg/m2.
The hallmark of the RS is a severe hypophosphoremia
[9] that is more likely to occur in severely malnourished
patients [10]. Its prevalence is from 28 up to 45 % dur-
ing refeeding, but literature shows that lower incidence
(about 5 %) is reported in studies conducted on patients
who were given electrolytic supplementation despite
normal levels at admission [3] showing how its empirical
administration could reduce the incidence of electrolyte
anomalies. An increase of transaminases levels after ini-
tiating refeeding frequently occurs [7]. Such an increase
is commonly referred to as steatosis that can be consid-
ered the hallmark of refeeding related hepatic dysfunc-
tion and can occur with any form of feeding. The
suspected mechanisms are excess oral glucose adminis-
tration, excessive exposure of the liver to pro-
inflammatory cytokines and excess free fatty acid expos-
ure [7]. A liver ultrasound may be helpful to distinguish
starvation-induced hypertransaminasemia (normal ultra-
sound) where continued feeding is indicated from
refeeding-induced hypertransaminasemia (steatosis on
ultrasound) where a caloric reduction and a change of
feeding are needed.
Case presentation
We report of a 15 year-old girl admitted to the Depart-
ment of Pediatric Medicine for bradycardia in anorexia
nervosa. The onset of her medical history dates back
12 months before admission when the girl started dieting
under medical supervision because she was overweight
(90 Kg. BMI 33.5 kg/m2). Despite the attainment of target
weight she continued the diet with a progressively more
marked restriction of food intake until she weighed just 38
Kg with BMI of 14 kg/m2, representing 63 % of her ideal
body weight. Upon admission, the patient was cachectic
and she had severe bradycardia (heart rate of 35 bpm),
blood pressure of 80/60 mmHg, hypothermia, dry skin,
subcutaneous emphysema on the neck and shoulders,
constipation and amenorrhea for 5 months. The girl
showed marked mood deflection with a high level of gen-
eralized anxiety and distorted perception of body image
with an intense fear of gaining weight. The blood exami-
nations showed: GOT 61 UI/L (normal range, 5–40 UI/L),
GPT 92 UI/L (normal range, 5–40 UI/L), total cholesterol
460 mg/dl (normal range, 140–200 mg/dl) and triglycer-
ides 188 mg/dl (normal range, 60–170 mg/dl). Abdominal
ultrasound was normal, as well as chest X-ray. After a
careful multidisciplinary assessment the girl underwent
intravenous rehydration (with 5 % glucose solution, so-
dium and potassium supplementation) and both psycho-
logical support program and antipsychotic therapy with
aripiprazole and fluoxetine were started. Despite this ap-
proach the patient kep on refusing food and losing weight
so she was subjected to forced enteral feeding with naso-
gastric tube. Over the following weeks blood tests showed
gradual worsening of hypertransaminasemia. Infections,
autoimmune conditions, metabolic diseases and iatrogenic
causes were investigated and excluded. In particular, even
if prescribed antipsychotic therapy could be potentially in-
volved in increasing of transaminase levels, its role was ex-
cluded because of the low dose (aripiprazole at 2.5 mg/day
and fluoxetine at 10 mg/day) and the lack of improving
after its discontinuation. The weight reached a minimum
of 35 kg and did not improve (Fig. 1). Enteral nutrition
(EN) was reduced and parenteral nutrition (PN) was later
started with a significant increase of both caloric intake
(until 35 kcal/kg/d) and transaminases. The liver function
tests showed maximum values of GOT 1003 UI/L and
GPT 1784 UI/L after about a month of hospitalization
(Fig. 2) and signs of hepatic steatosis on the ultrasound
were simultaneously described. The subcutaneous emphy-
sema was gradually reduced but the onset of bilateral pre-
tibial edema was observed. Ten days after the beginning
of PN severe hypophosphoremia (0.4 mg/dl; normal range,
Fig. 1 Weight trend during hospitalization. The weight is expressed in kilograms (kg). The hospitalization is expressed in days of recovery on the X axis
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2.7–4.5 mg/dl) and isolated macrocytic anemia (Hb
6.9 mg/dl and MCV 100 fl) were observed. This evidence,
associated with the persistence of hypertransaminasemia
and peripheral edema, led to suspicion of refeeding dis-
order. So a progressive restriction of caloric intake (Fig. 3)
and a specific electrolyte and vitamin supplementation
were implemented with subsequent gradual improvement
of blood values and clinical condition of the patient. After
about two months of hospitalization a satisfactory weight
of 45 Kg (BMI 16.8 kg/m2) was reached. At now, one year
after discharge from hospital, the girl again weighs 85.7
Kg (BMI 30.8 kg/m2). Despite the periodic clinical and
neuropsychiatric evaluations, the eating disorder has not
been overcome.
Conclusion
None of the laboratory or clinical aspects of our case
remain unexplained neither those ralated to disease nor
those related to the complications of refeeding. In par-
ticular, the hypercholesterolemia and the hypertransami-
nasemia we observed at admission are both related to
starvation and well described in literature. After refeed-
ing the former improved progressively and the latter
worsened because of the establishment of mechanisms
related to the refeeding and described previously. How-
ever, as observed in several studies, it gradually normal-
ized after restriction of caloric intake. The only aspect of
hyperaminotransferasemia that differs from scientific
evidence is related to the time of its onset. The patient
had a delayed increase of liver function tests with max-
imum values a month after admission and forced refeed-
ing, contrary to the earlier onset reported in literature.
We are not able to give a complete explanation of this
data; probably it is due to the caloric intake being in-
creased to quickly as a result concomitant EN and PN.
Furthermore this nutritional approach didn’t allow us to
Fig. 2 Transaminases, cholesterol and triglycerides trends during hospitalization. The transaminases (GPT: Glutamic Pyruvic Transaminase; GOT: Glutamic
Oxaloacetic Transaminase) are expressed in UI/L, cholesterol and triglycerides in mg/dl. The hospitalization is expressed in days of recovery on the X axis
Fig. 3 Caloric intake variation during hospitalization related to refeeding way. The hospitalization is expressed in days of recovery on the X axis.
The refeeding ways reported on the top of the figure are Enteral Nutrition (EN) and Parenteral Nutrition (PN), even if also intravenous (IV) fluids
have been administered during more than one half of the hospitalization. The calculated caloric intake does not include the share of the oral one
started at day 36 of hospitalization
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distinguish the role of enteral caloric intake from the paren-
teral one. Regarding macrocytic anemia, the normalization
of the values after supplementation of folate and B12
vitamin which was followed by the gradual regularization of
diet later on, supports the hypothesis of their deficiency
even if their hematic levels were not investigated. Finally
hypophosphatemia is not a rare condition because it is the
hallmark of the RS and it must always be investigated in all
patients who undergo refeeding in order to perform a spe-
cific electrolyte supplementation and a possible change of
diet plan, as we did. However the step prior to the manage-
ment of hypoP could be its prevention even if no guidelines
exist for prophylactic phosphate dosing [11].
Weight gain is the final target of refeeding and it is
also associated with shorter hospitalization. However
many authors confirm a direct link between energy in-
take, hypophosphoremia and other refeeding distur-
bances, underscoring the need to identify approaches
that simultaneously maximize weight recovery and
minimize associated risks. The best way to balance such
aspects is the early identification of high risk patients. In
particular ideal body weight percentage at admission
(<70 % of expected body weight) is predictive of the
development of hypoP [11, 12].
For many years an initial low calorie approach and a
slow increase have been recommended [1, 8] even if dif-
ferent ranges of energy intake have been proposed [1, 2]
particularly at the beginning, and there is lack of consen-
sus about the best way to administer nutritional intake.
Recently, different studies report a higher caloric intake,
particular in mildly and moderately malnourished pa-
tients. However a lower caloric approach is still recom-
mended for severely malnourished patients (BMI <
15 kg/m2) because of the higher risk of complication of
refeeding [10]. Until now, the lack of consensus and am-
bivalence about appropriate refeeding intake remain in-
consistent and guidelines seem to be based on clinical
experience rather than scientific evidence [8]. So it is not
possible to suggest any initial energy intake prescription
as the safest, most efficient or preferable but the evalu-
ation of nutritional status of patients at admission, the
identification of risk factors for RS and the rapid identifi-
cation of complications must be considered to allow us
to manage the patient as best we can. Individualized diet
plan based on standardized indications is advisable for
patients with AN even if it is described that patients re-
ceiving standardized treatment have an accelerated
weight gain without increasing of the incidence of RS
compared to persons receiving individualized caloric
prescriptions [13]. So, further studies are mandatory to
define such issue. Finally, attention should be paid to the
follow-up of these fragile patients even after discharge to
prevent the recurrence of eating disorders which is not
unlikely, as in our case.
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